|
|
Upfront Briefing
Three FDA actions and a landmark ADC readout, and it isn't even Tuesday. GSK's Hansoh-partnered B7-H3 ADC posted the first Phase 3 overall-survival win the target class has ever managed — in any tumour type. Sanofi got the first on-body injector ever cleared for an anticancer drug, thirteen days ahead of its own deadline. And Elevar collected a third rejection on the same liver-cancer file, which at this point is less a regulatory setback than a tradition.
The through-line is China. Two of today's three leads are China-origin assets in Western hands, and the pipeline behind them keeps filling — a $52M Series B landed this weekend for an AI-designed oral GLP-1 already in Phase 3 in Hangzhou. The FDA also switched the lights back on, publishing 14 complete response letters after last week's pause. Rejection letters are public again, which is either transparency or a spectator sport, depending on whether you're long the name.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,575.4 |
+0.4% |
+10.5% |
| Nasdaq 100 |
29,825.1 |
+0.3% |
+18.3% |
| Russell 2000 |
2,977.8 |
(0.5%) |
+18.7% |
| Healthcare (XLV) |
160.8 |
(0.8%) |
+3.4% |
| Biotech (XBI) |
159.0 |
(3.2%) |
+30.9% |
| Nasdaq Biotech (NBI) |
6,644.4 |
(2.6%) |
+16.4% |
| Clinical Trials (BBC) |
53.2 |
(3.1%) |
+41.3% |
|
- Sector: a high-beta unwind, not a headline. Moderna (11%), ImmunityBio (8%) and Sarepta (8%) all broke lower with no negative catalyst on the tape, while Lilly fell just 3% and J&J 1% — money rotating out of pre-profit biotech and parking in large-cap pharma. XBI's equal weighting amplified it into a 3.2% index print.
- Macro: the S&P held green on a narrow bid — Nvidia +4% and Meta +6% carried the index while SK Hynix's $26.5B Nasdaq debut, the largest-ever US listing by a foreign issuer, opened 14% above its $149 ADR price. Oil eased (WTI settled $71.41, down 67c) as Washington signalled talks with Tehran would continue, but the 10-year at 4.568% and June CPI/PPI landing this week kept duration-heavy names on the back foot.
- Market data: U.S. cash close Friday, 10 July 2026.
The Big 3
|
1
|
GSK-Hansoh B7-H3 ADC posts Phase 3 win in SCLC
|
- Risvutatug rezetecan, a B7-H3 ADC, met the primary endpoint of overall survival in a Phase 3 small cell lung cancer study, supporting a regulatory submission in China.
-
Why it matters: ARTEMIS-008 is the first Phase 3 OS win for a B7-H3-targeted ADC in any tumour type — the class finally has pivotal proof of concept, and GSK owns the ex-Greater China rights for $185M upfront and up to ~$1.7B in milestones, struck in December 2023. That looks cheap now. The competitive read is against Amgen's Imdelltra, which took full FDA approval in November 2025 and EC clearance in June, and Jazz's Zepzelca: an ADC would enter a setting with no approved ADC and no CRS step-up dosing to manage. The catch is that the win is Chinese-population, topotecan-controlled, and no numbers were disclosed. The trade that matters is GSK's global EMBOLD SCLC-301, which reads out next year — and it carries the same China-sourced overhang the COINS Act keeps threatening to formalise.
-
Source:
Fierce Biotech
-
More:
BioSpace;
GSK;
|
|
2
|
FDA approves Sanofi's Sarclisa on-body injector
|
-
The FDA approved subcutaneous Sarclisa Escena across all existing IV indications in multiple myeloma — 13 days ahead of an extended 23 July action date — making it the first anticancer treatment deliverable by on-body injector in the US.
-
Why it matters: IRAKLIA (n=531) hit both coprimary endpoints — ORR and trough concentration — with a fixed 1,400mg dose through Enable Injections' CirCLIQ injector versus 10mg/kg IV, both on a pom-dex backbone. Non-inferior, faster, fewer infusion reactions. Note the timing: the FDA had pushed this file to 23 July and then cleared it early, which is not what a shaky review looks like. The commercial question is harder. Darzalex Faspro already owns the convenience argument with a five-minute push, so Sanofi is attacking a moat rather than digging one — the OBI is a differentiator only if community oncology reimburses the device and the chair-time saving lands with practice economics, not just patients. Watch new-patient starts, not total scripts.
-
Source:
Fierce Pharma
-
More:
PR
|
|
3
|
FDA turns the lights back on — 14 CRLs published, Elevar's third among them
|
-
The FDA resumed publishing complete response letters after last week's pause, posting 14 at once — including a third rejection for Elevar and Hengrui's camrelizumab-plus-rivoceranib in first-line unresectable or metastatic HCC, again on manufacturing deficiencies rather than efficacy.
-
Why it matters: Published CRLs change how the sector gets priced. The rejection letter used to be a company's own account of why it got rejected; now it's the agency's. That compresses an information gap small-cap biotech has traded on for years, and it means the next CRL in your book gets read by everyone, in the FDA's words, on the day. Elevar is the case study: three letters, all CMC, none about the data. Manufacturing failures compound — each remediation cycle burns cash and resets the clock while the 1L HCC window closes behind Tecentriq-Avastin and Imjudo-Imfinzi. The read for anyone underwriting China-origin oncology is that the clinical package is now the easy part, and from this week the failure mode is a matter of public record.
-
Source:
BioCentury
-
More:
Fierce Pharma;
|
Everything Else that broke
-
Bausch + Lomb killed BL1107 in glaucoma after the alpha-2B agonist missed its primary endpoint on visual sensitivity at Day 28 in a 159-patient Phase 2; the asset came from its $28M-upfront Whitecap Biosciences buy, and focus now shifts to the sustained-release implant WB006 in geographic atrophy, with trials not starting until 2028. — Fierce Biotech
- AAIC 2026 opened in London (12–15 July), where Leqembi's subcutaneous autoinjector matched IV efficacy and safety in early Alzheimer's — Eisai/Biogen defending share against Lilly's Kisunla on convenience rather than data. — PR
- Roche ended its Huntington's gene-silencing programs and scrapped two partnered studies. — STAT
- EMA's PRAC flagged new safety information for contraceptives and Litfulo. — EMA
- SCENESSE won Health Canada approval for EPP, expanding the rare-disease product's footprint. — PR
- Hemab's HMB-002 drove at least 2.4-fold peak VWF and FVIII increases in von Willebrand disease. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
Our H1 2026 Biotech M&A Report is live — deal volume, premiums, and who's actually buying.
-
Antengene received a $60M upfront payment from UCB, adding immediate non-equity cash. — PR
-
Insilico and CMS expanded their AI-powered CNS R&D collaboration. — PR
-
Santhera expanded AGAMREE's Biomedica distribution into five Central Asia and Caucasus markets. — PR
-
Qiagen is drawing reported early takeover interest from EQT, Advent and KKR at an indicated $50+ per share; no approach has been confirmed by the company. — Fidelity
-
Apollo agreed a €3B minority equity investment in Bayer's contraceptives business — a private carve-out, not a public offering. — Fierce Pharma
VC / Private Financings
-
MindRank AI raised a $52M Series B to fund MOBILE, the ~750-patient Phase 3 of MDR-001 — an AI-designed oral small-molecule GLP-1 agonist — in obesity in China. Round led by an unnamed group of institutional and healthcare funds; Kaiwu Capital advised. Syndicate not disclosed. — Fierce Biotech
IPOs / Follow-Ons
-
Apnimed filed its S-1 on 10 July to fund the launch of Oxnimbi (AD109) in obstructive sleep apnea, currently under FDA review after an April submission; LunAIRo (n=660) cut nightly apnea events 46.8% at 26 weeks versus 6.8% on placebo. Terms undisclosed. The company had $46.9M in cash in March after selling its Shionogi JV stake for $100M upfront, and is now run by Kevin Lind, who took Longboard to a $2.6B Lundbeck exit. — Fierce Biotech
|
Fourteen rejection letters, published on purpose. Somewhere an IR team is having a weekend. — BioBucks Team
|
|
|
